SGIOF Projected Dividend Yield

Ord/Shionogi & Co., Ltd. ( OTCBB : SGIOF )

Shionogi is the parent company of a group engaged in the research and development, purchase, manufacture and sale of pharmaceuticals, diagnostic reagents and medical devices. Co.'s principal prescription drugs are "Tivicay" for HIV treatment, "Mulpleta" for thrombocytopenia treatment, " Sympronic" for opioid-induced constipation treatment, " "Xofluza," influenza drug, and "Fetroja (cefiderocol)" for multidrug-resistant Gram-negative bacterial infection treatment. Co. is also engaged in the OTC drug business. Its principal products include "Sedes First," "Sedes Hi G," "Pylon," "Rapiacta Bag" and "Rapiacta Vial."

19 YEAR PERFORMANCE RESULTS